Observational data suggest apixaban leads to fewer thromboembolic events but higher bleeding risk, highlighting the need for individualized decision-making in dialysis patients.
Patients who received neoadjuvant systemic therapy followed by surgical resection for mucosal HNSCC in the US National Cancer Database (2004-2022) were evaluated using 1:5 propensity score matching to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results